Sanofi pays €120M to buy into AstraZeneca RSV program
Sanofi has paid €120 million ($126 million) upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against respiratory syncytial virus (RSV). The agreement will see Sanofi and AstraZeneca equally share costs and profits for a phase 2b asset with the potential to immunize infants against a virus that kills 160,000 children a year. AstraZeneca’s MedImmune picked up the rights to AIMM Therapeutics’ anti-RSV mAb D25 in 2009, and went on to initiate a phase 2b study in preterm infants in the back half of last year. Now, with the start of a phase 3 study in healthy f...
